Algae, Tree, Herbs, Bush, Shrub, Grasses, Vines, Fern, Moss, Spermatophyta, Bryophyta, Fern Ally, Flower, Photosynthesis, Eukaryote, Prokaryote, carbohydrate, vitamins, amino acids, botany, lipids, proteins, cell, cell wall, biotechnology, metabolities, enzymes, agriculture, horticulture, agronomy, bryology, plaleobotany, phytochemistry, enthnobotany, anatomy, ecology, plant breeding, ecology, genetics, chlorophyll, chloroplast, gymnosperms, sporophytes, spores, seed, pollination, pollen, agriculture, horticulture, taxanomy, fungi, molecular biology, biochemistry, bioinfomatics, microbiology, fertilizers, insecticides, pesticides, herbicides, plant growth regulators, medicinal plants, herbal medicines, chemistry, cytogenetics, bryology, ethnobotany, plant pathology, methodolgy, research institutes, scientific journals, companies, farmer, scientists, plant nutrition
Select Language:
 
   
 
 
Can't find? Try Deep Search with ePlantScience.com  
 
Share |
 
   
Main Menu
If navigation gets difficult, please click the main subject or sitemap to get the list of sub-categories
 
 
 
 
 
Related websites
 
 
 
 
 
 
 
 
Section: Genetics » Genetic Engineering and Biotechnology » Hybridoma and Monoclonal Antibodies
 
 
If you like this page, please click:  
 
 
  Alternatives to hybridoma for monoclonal antibodies
 
     
 
Content
Genetic Engineering and Biotechnology 5. Hybridoma and Monoclonal Antibodies
Hybridoma and the production of monoclonal antibodies
Improvements in hybridoma technology
Purification of antibodies
Antibody Engineering and Genetic Manipulations
Alternatives to hybridoma for monoclonal antibodies
Production of human and humanized antibodies
Uses of monoclonal antibodies
Monoclonal antibodies in diagnosis, screening and therapy
Vaccine production and monoclonal antibodies
Monoclonal antibodies as enzymes (abzymes)
Purification and quantitation of other molecules
Alternatives to hybridoma for monoclonal antibodies
In recent years, techniques have been developed, which allow production of monoclonal antibodies without hybridomas or even without the help of animals used for providing cells (lymphocytes and myeloma cells). For instance, antibody genes can be isolated from lymphocytes of immunized animals and then cloned and expressed in bacteria. The antibodies produced in bacteria under the control of cloned genes can be screened for binding to specific antigens. Thus, while hybridoma technology can immortalize antibody producing cells, gene technology immortalizes antibody producing genes. Computer graphic techniques are also being used to build specific antigen binding sites in antibodies. Using this approach some designer antibodies of practical value have already been produced. In this latter strategy genes are not really cloned from lymphocytes, but are instead designed from a repertoire of antibody genes available in a collection. These approaches, where hybridoma technology and/or the use of lymphocytes can be dispensed with for the production of Mab will be discussed in this section.

Bypassing hybridomas and cloning of Mab genes. The VH and VL genes for antibodies can be amplified through polymerase chain reaction (PCR) using 'universal primers' (universal primers will carry conserved sequences for most antibodies). By building restriction sites in the above primers, the amplified VH and VL genes can also be cloned directly for expression in mammalian cells or bacteria (Fig. 43.3). The raw material for PCR may be hybridomas or B cells, which may be homogenous (if derived from single cells) or heterogeneous. In the latter case, a variety of VH and VL genes will be amplified and will combine at random to produce as many as 106 clones for antibody genes (from 1000 different VH and 1000 different VL genes). These genes will be cloned in λphage and their products (particularly Fab fragments) can be screened for antigen binding activities. From such a large number of combinations in a combinatorial library, it is very difficult to recover the original pairs of V genes (e.g. VHa .VLa or VHx .VLx is a original pair; VHa .VLy is a new combination). However, the, complexity may be reduced by using antigen-selected B lymphocytes (filters coated with antigen can be used for screening). Different steps involved in cloning paired VH/VL genes are outlined in Figure 43.4.

PCR cloning of rearranged Vh and genes into expression vectors.
Fig. 43.3. PCR cloning of rearranged Vh and genes into expression vectors.
 
Strategies for cloning paired Vh and Vl genes from lymphocytes of an immunized animal.
Fig. 43.4. Strategies for cloning paired Vh and Vl genes from lymphocytes of an immunized animal.

Designing and building of Mab genes. The antigen binding sites of antibodies have been studied in some detail in recent years. This led to modelling of entirely new antibodies, sometimes for their use as enzymes. This modelling through computer graphics can be used for alteration of antibody genes or for synthesis of entirely new genes. These genes can be cloned and expressed in bacteria. The antibodies produced can be tested for their specificity and affinity for specific antigens. Primary and secondary libraries for antibody genes. In this method a repertoire of antibody genes can be prepared by using genes that can be obtained from a number of different sources including the following : (i) rearranged V genes from animals obtained through the use of PCR (with universal primers); (ii) new V genes obtained through gene conversion, a process adopted in birds; (iii) rearranged genes obtained from mRNA through reverse transcription; (iv) designing entirely new V genes or D segments. The next step is to allow the expression of library in bacteria and screen antibodies for antigen binding activities. The screening can be done on membrane filters coated with antigen. In future, the screening procedures may be replaced by methods of selection. In either case the selected VH and VL genes can be subjected to mutations to increase the affinity of an antibody for a specific antigen. A variety of methods for the above strategy are being developed, so that in future monoclonal antibodies will be produced without hybridomas and lymphocytes.

 
     






     
     
 
 
     
 
Copyrights 2009 © ePlantScience.com